<DOC>
	<DOC>NCT00800176</DOC>
	<brief_summary>This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus. Patients will be randomized to one of 6 groups to receive RO4998452 at doses of 2.5mg, 5mg, 10mg, 20mg or 40mg po daily, or placebo daily. Patients pre-treated with stable metformin will continue to take their usual dose of metformin throughout the study.The anticipated time on study treatment is &lt;=3 months</brief_summary>
	<brief_title>A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes, diagnosed for &gt;=3 months; either treated with diet, exercise and stable metformin, or with diet and exercise alone. type 1 diabetes mellitus; currently or within 2 months prior to screening treated with an oral or injectable antidiabetic agent except stable doses of metformin; currently or within 6 months prior to screening treated with any PPARgamma agonist; uncontrolled hypertension; significant prediagnosed diabetic complications requiring treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>